참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Isradipine | HCID 3784 | — |
| 반응물 | Methyl acetoacetate | HCID 7757 | — |
| 반응물 | Piperidine | HCID 8082 | — |
| 반응물 | 2,1,3-Benzoxadiazole-4-carbaldehyde | HCID 10290873 | — |
| 용매 | Acetic Acid | HCID 176 | — |
| 용매 | Diisopropyl Ether | HCID 7914 | — |
| 생성물 | 2-Acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester | HCID 53433213 | — |
반응 단계
To achieve the afore-mentioned objects, the present invention provides for a process for the manufacture of the Isradipine which, involves two steps. In the first step 2,1,3-benzoxadiazole-4-carboxaldehyde is reacted with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. The product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester is isolated and purified to get substantially high purity product with less than 0.3% 2,1,3-benzoxadiazole-4-carboxaldehyde content present in the purified product. In the second step the purified intermediate 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester is reacted with isopropyl-β-aminocrotonate in ethanol at 25 to 35° C. The crude Isradipine is crystallised from ethanol to get pure Isradipine having substantially higher purity and containing lower amount of the symmetrical ester isomers (III) and (IV).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07329756B2 |
|---|
| 출처 데이터셋 | uspto-grants-2008_02 |
|---|
| ORD ID | ord-391dc78fba9444bda56964b252ebf9ae |
|---|
| 출처 메모 | uspto-grants-2008_02 |
|---|